Khondrion receives Orphan Drug Designation for treatment of MELAS syndrome

Khondrion

12/8/15 - An orphan designation allows a pharmaceutical company to benefit from incentives to develop a medicine for a rare disease, such as reduced fees in protocol assistance and protection from competition once the medicine is placed on the market. Read more in the full press release.
 

Search Results